|APTSTAT3-9R STAT3 inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||N/A||SDF||Download SDF|
|Canonical SMILES||NC(CC1=CNC=N1)C(NC([H])C(NC(CC2=CC=CC=C2)C(NC(CCC(N)=O)C(NC(CC3=CNC4=C3C=CC=C4)C(N5C(C(NC([H])C(NC(CO)C(NC(CC6=CNC7=C6C=CC=C7)C(NC([[email protected]@H](C)O)C(NC(CC8=CNC9=C8C=CC=C9)C(NC(CCC(O)=O)C(NC(CC(N)=O)C(NC([H])C(NC(CCCCN)C(NC(CC%10=CNC%11=C%10C=CC=C%11)C(NC([[email protected]@H|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
Ki: 231 nmol/L
APTSTAT3-9R-9R is a STAT3 inhibitor.
STAT3 has been reported to promote the proliferation, survival, metastasis, immune escape, as well as drug resistance of cancer cells, making it a promising target for various diseases. However, though multiple STAT3 inhibitors and its regulatory or effector pathway elements have been identified, bioactive agents are limited.
In vitro: Previous study showed that APTSTAT3-9R bound to STAT3 with high specificity and affinity. Moreover, the addition of a cell-penetrating motif to the peptide to yield APTSTAT3-9R enabled uptake by murine B16F1 melanoma cells. In addition, treatment of various types of cancer cells with APTSTAT3-9R was able to inhibit STAT3 phosphorylation and reduce expression of STAT targets, such as Bcl-xL, cyclin D1, and survivin. As a result, APTSTAT3-9R could suppress the viability and proliferation of cancer cells .
In vivo: In a previous animal in vivo study, a human lung carcinoma xenograft model was prepared by subcutaneous implantation of A549 cancer cells. After tumors had reached a volume of approximately 50 mm3 after two weeks, APTSTAT3-9R was intratumorally injected every other day for a total of four injections. Results showed that the tumor burden was significantly reduced in the APTSTAT3-9R–treated group when compared with that in the control group; however, there was little difference in tumor size between APTscr-9R and control groups .
Clinical trial: Up to now, ALTSTADT3-9R is still in the preclinical development stage.
 Kim D,Lee IH,Kim S,Choi M,Kim H,Ahn S,Saw PE,Jeon H,Lee Y,Jon S. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res.2014 Apr 15;74(8):2144-51.